Annexon (NASDAQ:ANNX) Upgraded by The Goldman Sachs Group to “Hold” Rating

Annexon (NASDAQ:ANNX) was upgraded by research analysts at The Goldman Sachs Group to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on ANNX. Chardan Capital reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Monday, April 20th. Finally, Wall Street Zen raised shares of Annexon from a “sell” rating to a “hold” rating in a report on Saturday. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Annexon has an average rating of “Hold” and an average target price of $16.00.

Annexon Price Performance

Shares of ANNX stock opened at $5.44 on Tuesday. The company has a market capitalization of $891.29 million, a P/E ratio of -4.46 and a beta of 1.22. The company’s 50-day simple moving average is $5.70 and its two-hundred day simple moving average is $5.14. Annexon has a one year low of $1.67 and a one year high of $7.18.

Annexon (NASDAQ:ANNX) last issued its earnings results on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. On average, research analysts expect that Annexon will post -1.05 EPS for the current fiscal year.

Insider Activity at Annexon

In other news, CFO Jennifer Lew sold 7,851 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,118.61. Following the sale, the chief financial officer owned 113,765 shares in the company, valued at $581,339.15. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Overdorf sold 6,225 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $31,747.50. Following the completion of the sale, the executive vice president owned 124,464 shares in the company, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,513 shares of company stock valued at $165,973 in the last quarter. 12.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Annexon

Institutional investors and hedge funds have recently bought and sold shares of the business. Rhenman & Partners Asset Management AB boosted its position in Annexon by 78.9% during the third quarter. Rhenman & Partners Asset Management AB now owns 823,000 shares of the company’s stock worth $2,510,000 after acquiring an additional 363,000 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Annexon during the fourth quarter worth about $82,000. DNB Asset Management AS raised its stake in shares of Annexon by 40.0% in the 4th quarter. DNB Asset Management AS now owns 118,324 shares of the company’s stock valued at $594,000 after acquiring an additional 33,801 shares during the period. CWM LLC raised its stake in shares of Annexon by 29.0% in the 4th quarter. CWM LLC now owns 30,297 shares of the company’s stock valued at $152,000 after acquiring an additional 6,809 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after acquiring an additional 2,785 shares during the period.

Key Annexon News

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright lifted its earnings estimates for Annexon across multiple periods, including FY2026, FY2027, FY2028, and FY2029, signaling improved confidence in the company’s longer-term earnings trajectory.
• Positive Sentiment: The firm also raised near-term quarterly EPS forecasts for Q2, Q3, and Q4 2026, which may help reinforce investor sentiment around Annexon’s operating outlook.
• Neutral Sentiment: Separate market data showed short interest at zero shares, which does not appear to be a meaningful trading factor in the latest report.
• Neutral Sentiment: An awareness-month press release tied to Guillain-Barré syndrome was also published, but it did not include a direct business update or clinical catalyst for Annexon. Article Title

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.